Business
Press Release Oct 09 2020
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 09, 2020, titled "No significant clinical benefit with Umifenovir addition in COVID-19treatment: Glenmark clinical study".
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":" Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 09, 2020, titled \"No significant clinical benefit with Umifenovir addition in COVID-19treatment: Glenmark clinical study\". View Attachment","length":373,"tagName":"div"}]